| 參考文獻: | 英文部分
1.Barrett B. & Crawford D. (2002). “Integrating the intellectual property value chain”, Nat.Biotechnol. 20. Supplement pp.BE43-BE46. (http://www.nature.com/）
2.Bowonder, B., Thomas, M.T., Rokkam, V.M. & Rokkam, A. (2003). “The global pharmaceutical industry: changing competitive landscape”, Int. J. Technology Management, Vol.25, Nos.3/4, pp.201-226.
3.Cavalla D. (2003). “The extended pharmaceutical enterprise”, Drug Discov. Today, Vol.8, No.6, March 2003, p267-274.
4.Choi T.Y., Budny J. & Wank N. (2004). “Intellectual property management: a knowledge supply chain perspective”, Business Horizons 47/1, pp.37-44.
5.Drews J. (2003). ”Strategic trends in the drug industry”, Drug Discov. Today, Vol.8, No.9, pp.411-420.
6.Ganguli P. (2003). “Global pharmaceutical industry: intellectual wealth and asset protection”, Int. J. Technology Management, Vol. 25, Nos. 3/4, pp.284-313.
7.Mossinghoff G.J. & Bombelles T. (1996). “Intellectual property protection and the pharmaceutical Industry”, Oblon, Spivak. (http://www.oblon.com/)
8.Mossinghoff G.J. (2004). “Introduction to intellectual property rights: progress in the pharmaceutical industry”, USINFO Publications (http://usinfo.state.gov/products/pubs/intelprp/progress.htm.)
9.Parr R.L. & Sullivan P.H. (Editor). “Technology Licensing: corporate strategies for maximizing Value”, August 1996, Wiley publishers, pp.63-82.
10.Pitkethly R.H. (2001). “Intellectual property strategy in Japanese and UK companies: patent licensing decisions and learning opportunities”, Research Policy 30 pp.425-442.
11.Schaier A. (2001). “The provisional patent advantage: what is it and how to use it”, The Connecticut Law Tribune, April 16. (http://www.carmodylaw.com/CM/Articles/art_provisionals.asp)
12.Somaya D. & Teece D. J. (2000). ”Combining inventions in multi-invention products: organizational choices, patents, and public policy”, Haas school of business CCC Working Paper No.99-4.（http://papers.ssrn.com/sol3/papers.cfm?abstract_id=259889）
13.Somaya D. (2002). “Strategic determinants of decisions not to settle patent litigation in computer and research medicines”, Strategic Management Journal, 24(1), pp.17-38.
14.Somaya D. (2002). “Theoretical perspectives on patent strategy”, Working paper. (http://www.rhsmith.umd.edu/lbpp/dsomaya/Papers/Somaya-Theory.pdf) |
